MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, HOWL had -$11,882K decrease in cash & cash equivalents over the period. -$15,156K in free cash flow.

Cash Flow Overview

Change in Cash
-$11,882K
Free Cash flow
-$15,156K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Net loss
-16,370 -36,071
Stock-based compensation expense
1,233 3,799
Depreciation expense
402 832
Non-cash interest expense
551 1,010
Non-cash lease expense
198 381
Loss on extinguishment of debt
0 0
Change in fair value of derivative liability
25 190
Prepaid expenses and other assets
-457 574
Other receivables
0 0
Accounts payable, accrued expenses and other liabilities
-1,205 -2,348
Deferred revenue
0 0
Operating lease liability
-397 -951
Net cash used in operating activities
-15,156 -34,112
Purchases of property and equipment
0 0
Net cash used in investing activities
0 0
Proceeds from at the market offering of common stock, net of issuance costs
3,274 347
Proceeds from drawdown of term loans
0 0
Payment of debt issuance costs
0 0
Repayment of term loan
0 0
Proceeds from issuances under employee stock purchase plan
0 41
Proceeds from stock option exercises
0 0
Net cash provided by financing activities
3,274 388
Net decrease in cash, cash equivalents and restricted cash and cash equivalents
-11,882 -33,724
Cash and cash equivalents at beginning of period
112,215 -
Cash and cash equivalents at end of period
66,609 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Werewolf Therapeutics, Inc. (HOWL)

Werewolf Therapeutics, Inc. (HOWL)